Ignite Creation Date:
2025-12-24 @ 1:31 PM
Ignite Modification Date:
2025-12-31 @ 4:49 AM
Study NCT ID:
NCT01473095
Status:
COMPLETED
Last Update Posted:
2017-10-23
First Post:
2011-11-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
Sponsor:
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-11
Start Date Type:
None
Primary Completion Date:
2017-07-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-08-07
Completion Date Type:
ACTUAL
First Submit Date:
2011-11-10
First Submit QC Date:
None
Study First Post Date:
2011-11-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-10-19
Last Update Post Date:
2017-10-23
Last Update Post Date Type:
ACTUAL